A Phase III, 52-week, Open-label Study to Evaluate Long-term Safety of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Patients With Asthma
Phase of Trial: Phase III
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Salbutamol
- Indications Asthma
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline
- 31 Aug 2017 Planned End Date changed from 16 Jan 2019 to 1 Aug 2019.
- 31 Aug 2017 Planned primary completion date changed from 16 Jan 2019 to 1 Aug 2019.
- 26 Jun 2017 Status changed from not yet recruiting to recruiting.